The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer patients receiving atezolizumab: Analysis of individual participant data from IMvigor210 and IMvigor211

被引：0

作者：

Robesti, D. ^{[1
]}

Nocera, L. ^{[1
]}

Belladelli, F. ^{[1
]}

Schultz, J. G. ^{[2
]}

Fallara, G. ^{[1
]}

Marandino, L. ^{[3
]}

Raggi, D. ^{[3
]}

Montorsi, F. ^{[1
]}

Necchi, A. ^{[3
]}

Martini, A. ^{[4
]}

机构：

[1] IRCCS Osped San Raffaele, Urol Res Inst, Dept Urol, Dept Expt Oncol, Milan, Italy

[2] NCI, NIH, Bethesda, MD USA

[3] IRCCS Osped San Raffaele, Dept Oncol, Milan, Italy

[4] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX USA

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

A0535

引用

页码：S763 / S764

页数：2

共 32 条